Stay updated with breaking news from Liminal Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GPR84 antagonist program and OXER1 antagonist program on track to meet previously stated milestones in 2023Closed March 31, 2023 with just over CAD26.9 million cash on hand, expecting to provide... | June 16, 2023
LAVAL, QC and CAMBRIDGE, England, April 5, 2023 /PRNewswire/ -- Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), confirms that following close of markets on
CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery...
/PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its fourth quarter...
LAVAL, QC, and CAMBRIDGE, England, March 13, 2023 /PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its